BioCryst Pharmaceuticals BCRX Other Income (Expense)
Other Income (Expense) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's other income (expense)?
- BioCryst Pharmaceuticals (BCRX) reported other income (expense) of -$19.21M in Q1 2026.
- How has BioCryst Pharmaceuticals's other income (expense) changed year-over-year?
- BioCryst Pharmaceuticals's other income (expense) increased by 6.2% year-over-year, from -$20.47M to -$19.21M.
- What is the long-term trend for BioCryst Pharmaceuticals's other income (expense)?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's other income (expense) has grown at a 178.9% compound annual growth rate (CAGR), from $1.22M to -$73.6M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.